79
Participants
Start Date
November 30, 2011
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
questionnaire and interview
Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
Memorial Sloan-Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center
OTHER